LLY Stock Recent News
LLY LATEST HEADLINES
The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies are now trying to make waves in this space.
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity and diabetes rates collide with expanding middle-class incomes, the country is becoming a pivotal battleground for the two drugmakers.
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy.
Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are the price of admission to elite returns. No champion in the market rises without scar tissue.
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
Eli Lilly (LLY 1.12%) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might think it's too late to invest.
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services that make them recession resilient.